Last reviewed · How we verify

Roflumilast 500

Spanish Research Center for Respiratory Diseases · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Roflumilast 500 is a Small molecule drug developed by Spanish Research Center for Respiratory Diseases. It is currently FDA-approved.

Roflumilast 500 is a small molecule inhibitor of the enzyme phosphodiesterase 4. It is used to treat Chronic Obstructive Pulmonary Disease (COPD) as per a multicenter randomized double-blind clinical study.

At a glance

Generic nameRoflumilast 500
SponsorSpanish Research Center for Respiratory Diseases
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Roflumilast 500

What is Roflumilast 500?

Roflumilast 500 is a Small molecule drug developed by Spanish Research Center for Respiratory Diseases.

Who makes Roflumilast 500?

Roflumilast 500 is developed and marketed by Spanish Research Center for Respiratory Diseases (see full Spanish Research Center for Respiratory Diseases pipeline at /company/spanish-research-center-for-respiratory-diseases).

What development phase is Roflumilast 500 in?

Roflumilast 500 is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing